Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
4.490 ^USD	-0.88%		-12.30%	-26.99%

Jan. 27	Myriad Genetics, Inc. Advances Mrd Commercialization Timeline, Bolstered by New Study Data	CI
Jan. 14	Myriad Genetics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05:15 PM

Transcript : Myriad Genetics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05

Published on 01/14/2026 at 09:35 pm EST - Modified on 01/14/2026 at 10:50 pm EST

S&P Capital IQ

Presenter Speech
Unknown Analyst (Analysts)

Good evening, ladies and gentlemen. I'm [ Nischal Kapadia ]. I'm an associate with the Healthcare Investment Banking Group at JPMorgan. It's my pleasure to

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Myriad Genetics, Inc.

Jan. 27	Myriad Genetics, Inc. Advances Mrd Commercialization Timeline, Bolstered by New Study Data	CI
Jan. 14	Myriad Genetics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05:15 PM
Dec. 19	Indian Equities Rebound on Friday as Rupee Stability Lifts Sentiment	MT
Dec. 18	Zydus Lifesciences signs agreement with Myriad Genetics for cancer-risk tests in India	RE
Dec. 18	Zydus Lifesciences Limited Signs an Exclusive Agreement with Myriad Genetics	CI
Nov. 26	Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	MT
Nov. 25	Myriad Genetics Collaborates With Clairity, MagView to Roll Out AI Platform for Breast Cancer Risk Assessment	MT
Nov. 10	Myriad Genetics Expands Cancer Test With Additional Actionable Genes From NCCN Guidelines	MT
Nov. 03	Myriad Genetics Q3 revenue beats on volume growth in hereditary cancer testing	RE
Nov. 03	Myriad Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-31	Myriad Genetics, Inc. Announces A Post-Hoc Analysis of the Precision Medicine in Mental Health Care Study	CI
25-10-30	Neogen® Corporation Announces the Appointment of Bryan Riggsbee as Its Senior Vice President, Effective November 3, 2025	CI
25-10-30	Neogen® Corporation Announces the Appointment of Bryan Riggsbee as Chief Financial Officer, Effective November 3, 2025	CI
25-10-15	Kringle Pharma Establishes US Subsidiary to Accelerate Spinal Cord Injury Program	MT
25-10-01	Revance Appoints Scott Leffler as Chief Financial Officer, Effective October 1, 2025	CI